AlphaRx Announces Selection Of ARX828, A Novel INOS Inhibitor, For Advanced Preclinical Development

AlphaRx Inc. (OTC BB:
ALRX), a specialty pharmaceutical company announced that its ARX828,
an orally-administered, potent and selective inhibitor of iNOS (Inducible
Nitric Oxide Synthase), is advancing to preclinical studies to support an
investigational new drug (IND) application in 2008.



In animal models of inflammation, the anti-inflammatory activity of
ARX828 is significantly higher than Indomethacin and as effective as
Dexamethasone (a steroidal drug), but without the side-effects associated
with either of these drugs.



The Company has initiated two pivotal animal studies for ARX828 and
expects to receive results from these studies for analysis, by end of
November. The Company's goal is to develop ARX828 for the treatment of
Rheumatoid Arthritis and Inflammatory Bowel Disease.



About Rheumatoid Arthritis (RA)



There is no treatment currently available to cure RA. The goals of
treatment are to relieve pain, reduce inflammation, slow down joint damage
and improve function. Most RA patients require some form of DMARD--these
include methotrexate, an anti-cancer agent or the TNF-blocking agents such
as Enbrel. The TNF-blocking agents only inhibit the inflammatory mediator,
TNF, and require parenteral administration.



About Inflammatory Bowel Disease



Inflammatory bowel disease encompasses two chronic diseases that cause
inflammation of the intestines: ulcerative colitis and Crohn's disease. It
is estimated that 1,000,000 Americans suffer from IBD. The primary goal of
current treatment is to reduce and prevent inflammation that triggers
symptoms.



About AlphaRx Inc.



AlphaRx is a specialty pharmaceutical company utilizing proprietary
site-specific nanoparticulate drug delivery systems to develop novel
formulations of drugs that are insoluble or poorly soluble in water or have
yet to be administrable to the human body with an acceptable delivery
method. The Company also discovers and develops novel, small-molecule drugs
for the treatment of inflammatory diseases and neurodegenerative diseases.



Forward Looking Statements:



This release contains forward-looking statements within the meaning and
pursuant to the Safe Harbor provisions of the Securities Litigation Reform
Act of 1995 and involve risks and uncertainties that may individually or
mutually impact the matters herein described, including but not limited to
product development and acceptance, manufacturing, competition, regulatory
and/or other factors, which are outside the control of the companies.


AlphaRx Inc.

alpharma/pages/default.aspx



View drug information on Enbrel.